A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers. The name of the study drug involved in this study is: -Ivonescimab (a type of antibody)

Trial Details

NCT ID

NCT06805617

Phase

PHASE2

Sponsor

Glenn J. Hanna

Status

RECRUITING

Cancer Type

Salivary Gland Head and Neck Cancer

Interventions

Ivonescimab

Locations (sample)

Boston, Massachusetts, United States|42.35843,-71.05977
Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

Participants must have histologically confirmed salivary gland carcinoma (any histologic subtype, including ACC) with evidence of recurrent, metast…
Willing to provide tumor tissue from a diagnostic biopsy or prior surgery if deemed safe and feasible by the investigator.
Age 18 years or older at the time of consent. There is no upper age limit restriction in an effort to include patients across the lifespan.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →